Next Article in Journal
Metabolic and Biosynthetic Diversity in Marine Myxobacteria
Next Article in Special Issue
Fucosterol from an Edible Brown Alga Ecklonia stolonifera Prevents Soluble Amyloid Beta-Induced Cognitive Dysfunction in Aging Rats
Previous Article in Journal
Aspergixanthones I–K, New Anti-Vibrio Prenylxanthones from the Marine-Derived Fungus Aspergillus sp. ZA-01
Previous Article in Special Issue
The Protective Effects of Clams on Hypercholesterolemia in Late-Stage Triple-Transgenic Alzheimer’s Diseased Mice Hearts
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Marine Drugs
Volume 16
Issue 9
10.3390/md16090313
marinedrugs-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Cognitive Impairment in Chronic Obstructive Pulmonary Disease (COPD): Possible Utility of Marine Bioactive Compounds

by
Giulia Prinzi
1,
Alessia Santoro
1,
Palma Lamonaca
1,
Vittorio Cardaci
2,
Massimo Fini
3 and
Patrizia Russo
1,*
1
Clinical and Molecular Epidemiology, IRCSS San Raffaele Pisana, Via di Valcannuta 247, I-00166 Rome, Italy
2
Unit of Pulmonary Rehabilitation, IRCCS San Raffaele Pisana, Via della Pisana 235, I-00163 Rome, Italy
3
Scientific Direction, IRCSS San Raffaele Pisana, Via di Valcannuta 247, I-00166 Rome, Italy
*
Author to whom correspondence should be addressed.
Mar. Drugs 2018, 16(9), 313; https://doi.org/10.3390/md16090313
Submission received: 16 July 2018 / Revised: 30 August 2018 / Accepted: 30 August 2018 / Published: 4 September 2018
(This article belongs to the Special Issue Marine Compounds in Neurodegenerative Diseases)
Browse Figures
Versions Notes

Abstract

:
Chronic obstructive pulmonary disease (COPD) is characterized by long-term airflow limitation. Early-onset COPD in non-smoker subjects is ≥60 years and in the elderly is often associated with different comorbidities. Cognitive impairment is one of the most common feature in patients with COPD, and is associated with COPD severity and comorbidities. Cognitive impairment in COPD enhances the assistance requirement in different aspects of daily living, treatment adherence, and effectual self-management.This review describes various bioactive compounds of natural marine sources that modulate different targets shared by both COPD and cognitive impairment and hypothesizes a possible link between these two syndromes.

1. Introduction

Chronic obstructive pulmonary disease (COPD) causes chronic airflow limitation, breathlessness, exercise intolerance, cough, difficulty with daily activities, infections, and (re)hospitalization [1]. COPD pharmacological therapies are merely symptomatic, and not effective in disease modification and survival [1]. COPD is a multisystem disease, with effects beyond the lung and is associated with symptom burden and prognosis [2]. Many people with COPD have multiple other disorders [2]. The incidence of COPD in the general population is still increasing, and with an ageing population, this number is expected to increase further [3]. COPD is more prevalent in subjects older than 65 years of age. The onset of the disease is complex; multiple causes beyond smoking contribute to the development of COPD, such as environmental exposure, age-related degenerative changes, and genetic factors [4]. Thus, in elderly people, COPD is the result of different continuous gene–gene (G × G) and gene–environment (G × E) interactions that happen in the course of the life of a single person. COPD occurring at an earlier age than expected may result from the interaction of inherited factors and environmental exposures [5]. A seminal prospective study, published on 2014, of individuals 70 years and older, associates COPD with an increased risk of a-MCI or NA-MCI (mild cognitive impairement (MCI); amnestic MCI (a-MCI), and nonamnestic MCI (NA-MCI)). Moreover, the greatest risk for a-MCI and NA-MCI is among individuals with a duration of COPD longer than 5 years [6]. All of these data bring to light the importance of COPD as a risk factor for a-MCI and NA-MCI, highlighting the need for early intervention, to prevent or delay MCI onset and/or progression.

2. Mild Cognitive Impairment

The concept of MCI is evolving overtime, from the first definition of Reisberg and collaborators in the late 1980s [7,8,9,10,11,12,13,14], who considered MCI as an intermediate stage between normal ageing and dementia, to the definition of the National Institute on Aging-Alzheimer’s Association (NIA-AA) working group in 2011, who proposed new criteria for MCI [14]. The NIA-AA assumes that the decline in multiple (cognitive) domains, and single non-memory domain subtypes, are greater than would be expected considering the patient’s age, gender, and educational background [14]. The NIA-AA suggests that biomarkers may be used in research settings to aid in the identification of MCI subtypes (i.e., MCI due to AD or MCI that is unlikely due to AD). MCI matches to mild neurocognitive disorder in the new Diagnostic and Statistical Manual of Mental Disorders, fifth edition, (DSM-5). DSM-5 is the taxonomic and diagnostic tool published by the American Psychiatric Association (APA) that, in the United States, serves as the principal authority for psychiatric diagnoses and neurological disorders. [9]. A differentiation between MCI with amnestic MCI (a-MCI) or without impairments in memory domain is assumed (NA-MCI, (e.g., executive control, language, or visuospatial abilities)). Moreover, whereas a-MCI is presumed to have a high risk of converting to AD, subjects with NA-MCI have a high risk of converting to non-Alzheimer’s dementia [10]. Longitudinal studies have shown that MCI patients may return to a non-MCI diagnosis after some years [11,12]. These findings may imply either that MCI is a high risk but transient phase, or that diagnosis and/or screening is still unfocused. Indeed, different genetic and environmental factors may contribute to MCI [13].
Actually determining the primary underlying etiology of MCI is still a challenge, and is strictly dependent to the patient’s history. Some neuroimaging, genetic, and neuropsychological assessment may be considered as suggested by NIA-AA (see Table 1) [8,14,15,16,17,18,19,20,21,22].
Currently, there are no accepted pharmacologic treatments for MCI approved by the FDA (U.S. Food and Drug Administration), the EMA (European Medicines Agency), or the Pharmaceuticals and Medical Devices Agency in Japan. Table 2 reports the effect of different drug approaches on MCI, according to the Agency for Healthcare Research and Quality (USA) [23].
None of the proposed interventions has indicated effectiveness and/or helpfulness in delaying the progression from MCI to AD dementia [46,47,48,49]. Importantly, as highlighted recently by Petersen et al. [49], there are no high-quality, long-term studies recognizing pharmacologic or dietary drugs able to improve cognition and/or delay progression in patients with MCI. Moreover, Petersen et al. [49] recommended that patients diagnosed with MCI should avoid acetylcholinesterase inhibitors (AChEIs; authorized drugs for AD, i.e., donepezil, rivastigmine, galantamine), since these drugs show no benefit on cognitive outcomes or reduction in progression from MCI to dementia, and side effects, including gastrointestinal symptoms and cardiac concerns.
Thus, on the light of the heterogeneity of MCI, further studies testing different compounds in all of its subtypes are necessary to draw clear conclusions.

2.1. Association of Chronic Obstructive Pulmonary Disease with Mild Cognitive Impairment and Dementia

Starting in 2011, important studies [6,50,51], using standardized criteria, found that patients with moderate to severe COPD are at high risk for MCI. The association between COPD and MCI remains significant even after adjusting for cardiovascular comorbidities and other covariates (i.e., hypoxemia, hypercapnia). A recent systematic review and meta-analysis of observational studies, including 23,116 subjects with COPD with a mean age of 66.3 years, found that the prevalence of MCI is 25% [52]. These findings are in agreement with the most recent observations of Ouellette and Lavoie [53]. The prevalence of MCI in the general population is 8.4% for people of 65–69 years [49]. These data may suggest that in the presence of severe COPD, the percentage of MCI is higher than in the general population. Until now, no explanation has been proposed for this association. The underlying mechanisms of cognitive impairments in COPD are debatable and poorly understood. It has been hypothesized that serum clusterin (CLU) plays a role. In severe COPD patients, the levels of serum CLU are very high, and the level of serum CLU is negatively correlated with cognitive ability [54]. The peripheral CLU concentration is associated with mini-mental state examination (MMSE) score and brain atrophy in both MCI and AD patients [55,56]. Moreover, the CLU levels are higher in MCI individuals who convert to dementia after one year, than to non-converters [57]. Secretory CLU, also known as apolipoprotein J (apoJ), is a stress-activated ATP-independent molecular chaperone. CLU is a highly glycosylated glycoprotein of 80 kDa, consisting of two polypeptide chains connected by four to five disulfide bonds. CLU/ApoJ is involved in different transcriptional networks controlling protein homeostasis/proteostasis, apoptosis/pro-survival signaling [58]. On the other hand, it has been reported that, in human lung fibroblasts exposed to cigarette smoke, there is a high accumulation of CLU/ApoJ protecting, presumably, lung fibroblasts against cigarette smoke-induced oxidative stress [59].
It seems that the existing relationships between COPD and MCI are independent of the presence of comorbidities (i.e., vascular risk factors and stroke) [6,51]. COPD is associated with premature aging characterized by chronic inflammatory process [36], which may have a role in the cognitive impairment. Indeed, COPD shows different hallmarks of aging [36,60] such as follows:
  • i. Abnormal microRNA pattern. MicroRNAs (miRNAs), a class of small non-coding RNAs, are involved in post-transcriptional gene repression. Alterations in miRNA abundance occurs in lung tissue, inflammatory cells, and freely circulating cells in blood, and are thought to function both as drivers and modifiers of disease [61,62]. In COPD patients, -miR-124-3p, miR-34a, miR-124, miR-29c and miR-126 are upregulated; -miR-181c, miR-21, miR-146a, miR-98-5bp are downregulated [61]. In MCI/AD, miRNAs (miR-124-3p, miR-34a, miR-124, miR-181c, miR-21, miR-146a, miR-98-5bp) contribute to the development, differentiation, and synaptic plasticity of neuronal cells, and are involved in many neurodegenerative diseases, including AD [62].
  • ii. Activation of PI3K-mTOR signaling. PI3K-AKT-mammalian target of rapamycin (mTOR) pathway is critical for cellular senescence and aging. In parallel, mTOR is a negative regulator of autophagia. There is evidence for PI3K activation in the lungs and cells of COPD patients, as shown by increased expression of the downstream kinase phosphorylated Akt, which in turn activates mTOR [36]. mTOR has a critical role during cognitive function and memory and affects genetic pathways that lead to cognitive loss. An mTOR upstream signaling pathway, the PI3K/Akt axis, is observed in AD brain. Persistent activation of neuronal mTOR signaling is found in MCI and AD brains [63].
  • iii. Altered autophagy. Refers to a pathway of cellular self-digestion controlling the degradation of subcellular constituents, including misfolded proteins and damaged organelles. Increasing numbers of autophagic vacuoles are observed in COPD lung tissues under electron microscopy, whereas low vacuole formation is observed in control tissues. Autophagy and mitophagy play a complex role in the lungs, and its related phenomena can have both protective and injurious effects on the progression of COPD. Currently, there is no unifying explanation for the discrepancies between various studies [64]. Although the exact pathological role of autophagy in AD remains to be elucidated, autophagy inducers might provide a new effective therapeutic strategy by degrading aggregates in the early stages of AD. By contrast, the activation of autophagy might enhance disease severity during the late stages of AD, by accelerating Aβ-amyloid production.The autophagy–lysosome pathway is unable to “keep up” with the misfolded protein load that is built up, and becomes defective, causing the aggregation of protein [65]. A mutation in sequestosome1 (SQSTM1), a marker for autophagy that binds cargoes, is identified in patients with familial AD [66].
  • iv. Decreased anti-aging molecules. Many endogenous antiaging molecules counteract the mechanisms of senescence, and a reduction in their expression may accelerate the aging process [36]. Sirtuins, are recognized as antiaging molecules that regulate lifespan. Sirtuins are highly conserved NAD+-dependent deacetylases enzymes that play a role in resistance to stress, genomic stability, and energy metabolism. Defective sirtuins are proposed as a mechanism for accelerated lung aging in COPD. SIRT1, 120 kDa (actual size), levels are decreased in patients with COPD, as a result of oxidative stress [67]. SIRT1 decreases with increasing severity of lung emphysema and with a clinical history of frequent COPD exacerbations. Over-expression of a miR-34a causes a significant reduction in both mRNA and protein of SIRT1/-6 in COPD. The aging-suppressor gene, Klotho, is downregulated in COPD [67].There is no direct proof of different levels of SIRT1 in human AD, but overexpression of miR-34a decreases SIRT1 levels. Klotho protein is predominantly secreted by the choroid plexus of the brain, and protects hippocampal neurons from amyloid and glutamate toxicity via the activation of an antioxidant enzymatic system, suggesting Klotho is necessary for oligodendrocyte maturation and myelin integrity.The Klotho KL-VS variant is associated with an increase in the incidence of dementia in older men, in a dose-dependent fashion [68].
  • v. Defective DNA damage repair. Effective repair of DNA damage is essential for the survival of cells, and most individual organisms and species. Ineffective repair can result in cell death, cancer, and neurological disease. COPD and AD are associated with excessive DNA damage [69,70]. Several types of DNA damage are associated with neurodegeneration, including bulky adducts, abasic sites, DNA single-strand breaks (SSBs), DNA double-strand breaks (DSBs), base mismatches, insertions, and deletions. DNA repair inefficiency is common in COPD, and is correlated to progression. Poly (ADP-ribose) polymerase (PARP) activation is associated with the progression of COPD [71]. BRCA1 (originally breast cancer 1; currently BRCA1) critically contributes to DSB repair in central neurons and neuronal reductions [69]. BRCA1 causes increased persistence of DSBs, abnormal chromatin remodeling, cellular dysfunction, and cognitive deficits. Depletion of BRCA1 is found in brains of patients with MCI or AD. Depletion of BRCA1 is caused by the pathological accumulation of Aβ, which may promote the proteasomal degradation of BRCA1 through overactivation of extrasynaptic N-methyl-d-aspartate (NMDA) receptor [69].
  • vi. Cellular senescence. Senescence is a state of irreversible cell cycle arrest. Senescent cells accumulate in the lung of COPD patients leading to persistent secretory phenotype (SASP) factors, and contributing to increased tissue dysfunction and COPD severity [72]. p16 and p21 are upregulated in cells of COPD patients. Compared with controls, p21 level is significantly decreased in lymphocytes of AD patients, while p53 is increased [72].
  • vii. Epigenetic changes. They include DNA methylation, covalent modifications of histone proteins and non-coding RNAs, and increases or decreases in gene transcription. In patients with COPD, there is emerging evidence showing aberrant expression of epigenetic marks, such as DNA methylation, histone modifications, and microRNAs in blood, sputum, and lung tissue [73]. AD entails dramatic losses of histone H4 lysine 16 acetylated isoform (H4K16ac) in the proximity of genes linked to aging and AD. A targeted proteomics approach in human brains showed reduction of histone H3 lysine18 acetylation (H3K18ac) and histone H3 lysine 23 acetylation (H3K23ac) in AD [74].
  • viii. Immunosenescence. Immunosenescence affects both innate and adaptive immunity, leading to a loss of function, and is implicated in chronic inflammatory diseases. In COPD, there is reduced immunity, which results in a low-grade chronic inflammatory response. Cluster of differentiation 8 + 28 (CD8 + CD28) null cells from COPD patients have reduced histone deacetylase 2 (HDAC2) expression and are corticosteroid resistant [36]. Patients with mild AD show decreased percentages of naïve cells, elevated memory cells, and increased proportions of CD4+, but not CD8+ cells lacking the important costimulatory receptor CD28 [75].
  • ix. Mitochondrial dysfunction. The key function of mitochondria is to produce ATP through the coupling of oxidative phosphorylation with cellular respiration. Mitochondria play a crucial role in the maintenance of intracellular Ca2+ homeostasis, because they can take up substantial amounts of cytosolic Ca2+. COPD is linked to increased mitochondrial reactive oxygen species (ROS) production, decreased intracellular antioxidants, and reduced numbers of mitochondria. The mitochondrial stress markers Parkin and PTEN-induced protein kinase-1 (PINK1) are increased in COPD patients [36]. Mitochondrial deficiency has been suggested to be a hallmark of AD as the patients display early metabolic changes prior to the emergence of any histopathological or clinical abnormalities, showing reduced metabolism, disruption of Ca2+ homeostasis, increased levels of ROS, lipid peroxidation and apoptosis, as well as hyperphosphorylation, aggregation, and damage of axonal transport leading to abnormal mitochondrial distribution. These pathological features impair mitochondrial dynamics by regulating mitochondrial fission/fusion proteins, causing mitochondrial dysfunction and neuronal damage [76].
  • x. Stem cell exhaustion. Airway basal progenitor cells are crucial for lung health and resilience because of their ability to repair injured airways. Basal progenitor count, self-renewal, and multipotentiality are all reduced. COPD progenitors produce an epithelium with increased basal and mucous cells and decreased ciliated cells, replicating the COPD phenotype [77].
  • xi. Telomere shortening. Studies analyzing leukocyte telomere length (LTL) at the population level have provided ample evidence for the hypothesis that LTL shortening is associated with aging and with age-related chronic diseases (cardiovascular and metabolic disease, cancer), although some inconsistencies have been observed.The exact mechanisms leading to telomere shortening in association with COPD are not yet understood [36]. Increased oxidative stress impairs telomerase activity and, thus, may directly result in telomere shortening. Telomere shortening, in turn, leads to the activation of p21, resulting in cellular senescence and the release of proinflammatory mediators, such as interleukin (IL)-6 and chemokine CXCL8. The telomere length and its rate of shortening did not relate to clinical and lung function parameters [36]. Intermediate values in the aMCI subjects, and the lowest values in the AD patients, suggest a definite relationship between telomere reduction and AD development. Association between APOE genotypes and LTL is observed [78].
All of these data are useful for finding new molecules able to act both in COPD and in MCI/AD.

2.2. Marine Bioactive Compounds and COPD and MCI/AD

Today, ocean habitats are the newest frontier in drug medical research. Thus, starting in 1969, FDA/EMA approved eight drugs obtained by marine sources including important antineoplastic (cytarabine, eribulin, trabectidin) and anti-pain (ziconotide) compounds [79]. The actualization of this relatively new area of scientific exploration is based on continuous testimony of marine medicine that comes from 2953 BC during emperor Fu His in China, as a tax for profits of fish-derived medicine [80]. Actually, we published several reviews on this topic [81,82,83,84]. In one, we described the most promising agents from marine sources in the treatment of AD [84]. Here, Table 3 reports new marine bioactive compounds acting against different targets shared by COPD and MCI/AD.
Drug activities and drug mechanisms of action are investigated on cellular and/or in mouse model systems. Every marine bioactive compound is studied in a single disease (COPD or MCI/AD) model [66,85,86,87,88,89,90,91,92,93,94,95].
Fucoxanthin (Fx) is a xanthophyll, with chemical formula C42H58O6 (Figure 1), isolated from edible brown seaweeds firstly from Fucus, Dictyota, and Laminaria. In lung an inhibition of TGF-β1-induced phosphorylation of p38 mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K)/Akt, and Smad2/Smad3 (Smad2/3) after Fx treatment, has been observed. Collagen contraction decreased significantly upon Fx treatment. Intraperitoneal injection of Fx in mice inhibits bleomicyn-induced lung fibrosis [85]. Fx attenuates Aβ oligomer-induced neurotoxicity on SH-SY5Y cells (isolated from a bone marrow biopsy of a neuroblastoma used as “in vitro models” of neuronal function and differentiation) leading neuroprotective effects via regulating PI3K/Akt and ERK pathways [86].
Austrasulfone, with chemical formula C6H10O3S (Figure 2), from the soft coral Cladiella australis, collected in Taiwan waters, shows anti-apoptotic activity on neuronal cells SH-SY5Y mediated through the regulation of the Akt and heme oxygenase (HO)-1 signaling pathways [87].
TMC-256C1, with chemical formula C15H12O5 (Figure 3), isolated from an ethyl acetate extract of the marine-derived fungus Aspergillus sp. SF6354, activates p38 mitogen-activated protein kinases (MAPK) and PI3K/Akt signaling pathways in mouse BV2 microglial cells [88].
1-O-(Myristoyl) glycerol (MG), with chemical formula C17H34O4 (Figure 4), from the head of the fish Ilishaelongate, induces 42% of the neurite outgrowth of rat PC12 (rat adrenal gland pheochromocytoma) cells through the activation of ERK, cAMP responsive element-binding protein (CREB) and PI3K signaling pathways [89].
Sargaquinoic acid, with chemical formula C27H36O4 (Figure 5), from a marine brown alga Sargassum macrocarpum, enhances neuritere generation and protected rat PC12D cells from hydrogen peroxide-induced oxidative stress through PI3K signaling pathways [90].
Bafilomycin(s), with chemical formula C35H58O9 (Figure 6), a family of toxic macrolide antibiotics from marine Streptomyces griseus, inhibits autophagy by preventing fusion of autophagosomes with lysosomes [66].
Coibamide A, with chemical formula C65H110N10O16 (Figure 7), an antiproliferative depsipeptide isolated from a marine Leptolyngbya cyanobacterium, induces autophagy in an autophagy-related gene 5 (Atg5)-dependent manner [66].
Manzamine A, with chemical formula C36H44N4O (Figure 8), a β-carboline alkaloid isolated from the marine sponge Xestospongiaashmorica that acts as a GSK-3β inhibitor and papuamine, with chemical formula C25H40N2 (Figure 9), a pentacyclic alkaloid and antifungal agent, fromthe marine sponge Halicona, induces autophagy by increasing levels of microtubule-associated protein 1 light chain 3 (LC3) [66].
Apo-9′-fucoxanthinone (ApoF9), with chemical formula C15H22O4 (Figure 10), from brown algae Undariopsis peteseniana, decreases cigarette smoke extract-induced DNA damage in immortalized human bronchial epithelial cells via reduction of ATM (atypical kinase of the PIKK family) phosphorylation [91].
Antarctic krill oil (AKO), from Euphausia superb, is rich in polyunsaturated fatty acids, and two of the most important components are omega-3 fatty acids similar to those in fish oil (Alpha-linolenic acid (ALA) with chemical formula C18H30O2 (Figure 11a), docosahexaenoic acid (DHA)with chemical formula C22H32O2 (Figure 11b), eicosapentaenoic acid (EPA) with chemical formula C20H30O2 (Figure 11c)) and phospholipid-derived fatty acids (PLFA), mainly phosphatidylcholine with chemical formula C46H84NO8P (Figure 12). A protective effect was observed against AD in senescence-accelerated prone mouse strain8 (SAMP8). AKO ameliorates learning and memory deficits, and eases the anxiety by Morris water maze, Barnes maze, and open-field test. AKO reduces Aβ accumulation in hippocampus by decreasing the contents of malondialdehyde and 7,8-dihydro-8-oxoguanine, by increasing superoxide dismutase and glutathione peroxidase activities in the brain of SAMP8 mice [92].
A 43 kD protein, isolated from atlantic oysters, attenuates neuronal cell death induced by 100 mM d-galactose on human neurons-hippocampal (HN-h) cells in a dose-dependent manner. This protein alleviates mitochondrial inactivation, decreasing mitochondrial membrane potential oxidative stress, and fusion/fission state at non-cytotoxic concentrations of d-galactose-treated HN-h cells. The induced recovery of metallathionein-3 (MT-3) decreases and inhibits β- and γ-secretase, as well as Aβ accumulation in HN-h cells caused by d-galactose induction [93].
Gracilin(s), with chemical formula C15H20O3 (Figure 12), a family of diterpenoid compounds, isolated from the sponge Spongionella, in 3xTg-AD mice (triple-transgenic mouse model of AD, the only model that exhibits both Aand pathology characteristic of the human form), after chronicintraperitoneal treatments, in preliminary behavioral test, points to a positive trend on learning and spatial memory of treated mice. Gracilins decrease Aβ42 and hyperphosphorylated levels, inhibit ERK and β-secretase enzyme1 (BACE1),and preserves neurons against oxidative damage [94,95].

3. Discussion

The majority of new marine bioactive compounds are investigated in the field of neurodegeneration. COPD appears to be a neglected field of research. Nevertheless, according to the US Burden of Disease Collaborators, in 2016 COPD was the third cause of death in the United States, with an increasing trend in comparison with 2010 [96]. In Italy, COPD affects 3.5 million people, accounting for 55% of deaths/year among respiratory disease (3rd cause of death) [97]. COPD causes chronic airflow limitation, breathlessness, exercise intolerance, cough, difficulty with daily activities, infections, and (re)hospitalization [1]. COPD pharmacological therapies are merely symptomatic, and not effective in diseasemodification and survival [98]. Patients experience exacerbations, which contribute to high rates of emergency department (ED) visits, and in-patient admissions and readmissions, and high costs to the economy [99].The pattern of care for people with moderate–very severe COPD involves regular lengthy hospital admissions and rehospitalization for acute exacerbations (AECOPD), which result in high healthcare costs (Italy: 2723€/year/patient; 2617€/patient for ED) [99]. Costs increase with disease severity, presence of comorbidity, and rehabilitation [99], with an undesirable effect on the quality of life patient self-management. AECOPD accounts for 0.5% of ED visits, and are economically onerous [99]. Yet, most healthcare resources are poured into managing acute exacerbations that are only temporarily effective. AECOPD patients attending ED are old, affected by several comorbidities, and are burdened by a high prevalence of adverse outcome [99].
The first report of an association between COPD and AD is recordedin 1982 [100]. Since then, different studies, reporting this association, observed that either COPD worsens AD and increases the rate of MCI [6,50,51,53,54] or that AD worsens the severity of COPD [101,102,103]. This is a “vicious circle” that makes (self)-management difficult [103] especially for persons with neurocognitive impairments. Self-management in COPDimplies the personal ability to monitor symptoms, adhere to therapy, sustain an healthy lifestyle, and cope with the impact of diseases on daily functioning, emotions, and relationships [103]. There is contrasting evidence as to whether cognitive impairment (based on MMSE scores <24) is an independent predictor of poor-quality of spirometry [104,105]. Spirometry, a measure of forced expiratory volume in 1 s (FEV1), is a gold standard for the diagnosis and assessment of severity and follow-up of COPD [1].
Although, the present gold-standardrecommendations recognize comorbidities as important to COPD prognosis and severity, in general, they suggest that the presence of comorbidities should not alter COPD treatment, and “should be treated per usual standards regardless of the presence of COPD” [1]. This approach reflects the concept of “comorbidity” or “multi-morbidity” as a simple sum of single diseases. Actually, this concept appears misleading, possibly reflecting an oversimplification. It is well known now that a disease phenotype, the presentation of a disease in a given individual, reflects various pathobiological processes that interact in a complex network, involving genome, transcriptome, proteome, metabolome, and environment. The coexistence of two or more diseases in the same person raises the question of the presence of a possible common etiological pathway determined either by common disease genes or by a co-regulated cellular pathway, the so called “shared component hypothesis”. The shared component model, as proposed by Knorr-Held andBest [106], represents an easy approach to the joint spatial analysis of two related diseases. The key idea of the shared component model is to separate the underlying risk surface for each disease into a shared and a disease-specific component. At the molecular level, a disease may be considered as a disorder of a network of interactions, difficult to be considered as being independent of one to another [107,108]. Consecutively, a drug acting on a single target results in a phenotypic reaction caused by changes in the multi-dimensional networks, rather than exclusively in the target action. The network may be involved in (i) a unique disease pathway or (ii) belonging to multiple disease pathways. In this scenario,precision pharmacology (PP), a new theoretical paradigm, has in mind to help in exploring andpredicting the whole effect of a given drug at the systems level (molecular, cellular, tissue, organ, organism, and population levels) [109].The long-term goals of PP are both (i) developing multi-target therapeutic approaches for multifactorial diseases, such as COPD and AD; and (ii) finding frameworks of therapeutic efficacy/adverse risks [108,110].
Marine bioactive compounds, by nature, are often structurally complex compounds with efficacy relying on multitarget intervention via their multiple active components. Thus, they can be examined for developing network-based multicomponent drugs. The example of bryostatin (Bry-1), a potent modulator of PKC, initially isolated from the extract of Bugulaneritina, is emblematic of marine bioactive compounds’ potential, since Bry-1 is exploited in, according to the classic concept, different non-correlated diseases, such as cancer, HIV, and neurodegenerative diseases [84].
In Table 3, it appears that similar patterns are involved both in COPD and in MCI/AD. The same drug, such as fucoxanthin, is useful both against lung fibrosis and neurodegeneration [85,86]. Moreover, Fx may reverse scopolamine-induced impairments of cognition in mice, increasing choline acetyltransferase (ChAT) activity and brain-derived neurotrophic factor (BDNF) expression, and decreasing AChE activity in the brains. Moreover, Fx directly inhibits AChE in a non-competitive manner in vitro, possibly interacting with the peripheral anionic site within AChE [111]. In scopolamine-induced cognitive impairments, oxidative stress plays an important role, thus, it may be possible to speculate that Fx reverses impairments of cognition, reducing the oxidative stress increase. Patients affected by COPD and MCI/AD may benefit from Fx administration. However, additional experiments to address this shall be planned.
A recent paper revised the literature for the selection of cancer genes for the multitargeted use of existing drugs and natural products [112]. The authors used network analysis and a search tool for retrieval of interacting genes/proteins (STRING), to study the possible interactions to show the links between antioxidants, antibiotics, anti-inflammatory and antimitotic agents and their targets, for their possible use in cancer. After network analysis, they obtained a shortlist of 22 genes based on their average shortest path length, connecting one node to all other nodes in a network [112]. The selected genes were then analyzed with STRING for their protein–protein interactions. Accordingly, the authors proposed the selected genes to be regarded as main targets, and used in finding marine bioactive compounds as drug leads in cancer treatment.
We hereby suggest a screening of marine bioactive compounds having antioxidant, anti-inflammatory, anti-mitochondrial dysfunction, and anti-accelerated aging activity on COPD and MCI/AD models.

Author Contributions

All authors contributed equally to the review.

Funding

This work was supported by funding of the Italian Ministry of Health.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Available online: https://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd (accessed on 4 July 2018).
  2. Vanfleteren, L.E.; Spruit, M.A.; Wouters, E.F.; Franssen, F.M. Management of chronic obstructive pulmonary disease beyond the lungs. Lancet Respir. Med. 2016, 4, 911–924. [Google Scholar] [CrossRef]
  3. Soriano, J.B.; Abajobir, A.A.; Abate, K.H.; Abera, S.F.; Agrawal, A.; Ahmed, M.B.; Aichour, A.N.; Aichour, I.; Aichour, M.T.E.; Alam, K.; et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir. Med. 2017, 5, 691–706. [Google Scholar] [CrossRef]
  4. Agustí, A.; Faner, R. COPD beyond smoking: New paradigm, novel opportunities. Lancet Respir. Med. 2018, 6, 324–326. [Google Scholar] [CrossRef]
  5. Stoller, J.K.; Lacbawan, F.L.; Aboussouan, L.S. Alpha-1 Antitrypsin Deficiency. In GeneReviews®; Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Stephens, K., Amemiya, A., Eds.; University of Washington: Seattle, WA, USA, 2006. [Google Scholar]
  6. Singh, B.; Mielke, M.M.; Parsaik, A.K.; Cha, R.H.; Roberts, R.O.; Scanlon, P.D.; Geda, Y.E.; Christianson, T.J.; Pankratz, V.S.; Petersen, R.C. A prospective study of chronic obstructive pulmonary disease and the risk for mild cognitive impairment. JAMA Neurol. 2014, 71, 581–588. [Google Scholar] [CrossRef] [PubMed]
  7. Reisberg, B.; Ferris, S.H.; de Leon, M.J.; Franssen, E.S.E.; Kluger, A.; Mir, P.; George, A.E.; Shulman, E.; Steinberg, G.; et al. Stage-specific behavioral, cognitive, and in vivo changes in community residing subjects with age-associated memory impairment and primary degenerative dementia of the Alzheimer type. Drug Dev. Res. 1988, 15, 101–114. [Google Scholar]
  8. Dubois, B.; Albert, M.L. Amnestic MCI or prodromal Alzheimer’s disease? Lancet Neurol. 2004, 3, 246–248. [Google Scholar] [CrossRef]
  9. Diagnostic and Statistical Manual of Mental Disorders, 5th ed.; American Psychiatric Association: Arlington, VA, USA, 2013.
  10. Petersen, R.C.; Negash, S. Mild cognitive impairment: An overview. CNS Spectr. 2008, 13, 45–53. [Google Scholar] [CrossRef] [PubMed]
  11. Ganguli, M.; Dodge, H.H.; Shen, C.; DeKosky, S.T. Mild cognitive impairment, amnestic type: An epidemiological study. Neurology 2004, 63, 115–121. [Google Scholar] [CrossRef] [PubMed]
  12. Ritchie, K. Mild cognitive impairment: An epidemiological perspective. Dialogues Clin. Neurosci. 2004, 6, 401–408. [Google Scholar] [PubMed]
  13. Apostolo, J.; Holland, C.; O’Connell, M.D.; Feeney, J.; Tabares-Seisdedos, R.; Tadros, G.; Campos, E.; Santos, N.; Robertson, D.A.; Marcucci, M.; et al. Mild cognitive decline. A position statement of the Cognitive Decline Group of the European Innovation Partnership for Active and Healthy Ageing (EIPAHA). Maturitas 2016, 83, 83–93. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Albert, M.S.; DeKosky, S.T.; Dickson, D.; Dubois, B.; Feldman, H.H.; Fox, N.C.; Gamst, A.; Holtzman, D.M.; Jagust, W.J.; Petersen, R.C.; et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011, 7, 270–279. [Google Scholar] [CrossRef] [PubMed]
  15. Hansson, O.; Zetterberg, H.; Buchhave, P.; Londos, E.; Blennow, K.; Minthon, L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol. 2006, 5, 228–234. [Google Scholar] [CrossRef]
  16. Fennema-Notestine, C.; Hagler, D.J.; McEvoy, L.K.; Fleisher, A.S.; Wu, E.H.; Karow, D.S.; Dale, A.M. Structural MRI biomarkers for preclinical and mild Alzheimer’s disease. Hum. Brain Mapp. 2009, 30, 3238–3253. [Google Scholar] [CrossRef] [PubMed]
  17. Herholz, K. Cerebral glucose metabolism in preclinical and prodromal Alzheimer’s disease. Expert Rev. Neurother. 2010, 10, 1667–1673. [Google Scholar] [CrossRef] [PubMed]
  18. Corder, E.H.; Saunders, A.M.; Strittmatter, W.J.; Schmechel, D.E.; Gaskell, P.C.; Small, G.W.; Roses, A.D.; Haines, J.L.; Pericak-Vance, M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993, 261, 921–923. [Google Scholar] [CrossRef] [PubMed]
  19. Strittmatter, W.J.; Saunders, A.M.; Schmechel, D.; Pericak-Vance, M.; Enghild, J.; Salvesen, G.S.; Roses, A.D. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 1993, 90, 1977–1981. [Google Scholar] [CrossRef] [PubMed]
  20. Bonanni, L.; Thomas, A.; Onofrj, M. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 2006, 66, 1455. [Google Scholar] [CrossRef] [PubMed]
  21. Weintraub, S.; Wicklund, A.H.; Salmon, D.P. The neuropsychological profile of Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012, 2, a006171. [Google Scholar] [CrossRef] [PubMed]
  22. Seelaar, H.; Kamphorst, W.; Rosso, S.M.; Azmani, A.; Masdjedi, R.; de Koning, I.; Maat-Kievit, J.A.; Anar, B.; Donker Kaat, L.; Breedveld, G.J.; et al. Distinct genetic forms of frontotemporal dementia. Neurology 2008, 71, 1220–1226. [Google Scholar] [CrossRef] [PubMed]
  23. Kane, R.L.; Butler, M.; Fink, H.A.; Brasure, M.; Davila, H.; Desai, P.; Jutkowitz, E.; McCreedy, E.; Nelson, V.A.; McCarten, J.R.; et al. Interventions to Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer’s-Type Dementia. In Comparative Effectiveness Reviews; Agency for Healthcare Research and Quality: Washington, DC, USA, 2017; Volume 188. [Google Scholar]
  24. Lee, L.K.; Shahar, S.; Chin, A.V.; Yusoff, N.A. Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): A 12-month randomised, double-blind, placebo-controlled trial. Psychopharmacology 2013, 225, 605–612. [Google Scholar] [CrossRef] [PubMed]
  25. Gavrilova, S.I.; Preuss, U.W.; Wong, J.W.; Hoerr, R.; Kaschel, R.; Bachinskaya, N.; GIMCI Plus Study Group. Efficacy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: A randomized, placebo-controlled, double-blind, multi-center trial. Int. J. Geriatr. Psychiatry 2014, 29, 1087–1095. [Google Scholar] [CrossRef] [PubMed]
  26. DeKosky, S.T.; Williamson, J.D.; Fitzpatrick, A.L.; Kronmal, R.A.; Ives, D.G.; Saxton, J.A.; Lopez, O.L.; Burke, G.; Carlson, M.C.; Fried, L.P.; et al. Ginkgo biloba for prevention of dementia: A randomized controlled trial. JAMA 2008, 300, 2253–2262. [Google Scholar] [CrossRef] [PubMed]
  27. Cherrier, M.M.; Anderson, K.; Shofer, J.; Millard, S.; Matsumoto, A.M. Testosterone treatment of men with mild cognitive impairment and low testosterone levels. Am. J. Alzheimers Dis. Other Demen. 2015, 30, 421–430. [Google Scholar] [CrossRef] [PubMed]
  28. Kato-Kataoka, A.; Sakai, M.; Ebina, R.; Nonaka, C.; Asano, T.; Miyamori, T. Soybean-derived phosphatidylserine improves memory function of the elderly Japanese subjects with memory complaints. J. Clin. Biochem. Nutr. 2010, 47, 246–255. [Google Scholar] [CrossRef] [PubMed]
  29. Naeini, A.M.; Elmadfa, I.; Djazayery, A.; Barekatain, M.; Ghazvini, M.R.; Djalali, M.; Feizi, A. The effect of antioxidant vitamins E and C on cognitive performance of the elderly with mild cognitive impairment in Isfahan, Iran: A double-blind, randomized, placebo-controlled trial. Eur. J. Nutr. 2014, 53, 1255–1262. [Google Scholar] [CrossRef] [PubMed]
  30. Smith, A.D.; Smith, S.M.; de Jager, C.A.; Whitbread, P.; Johnston, C.; Agacinski, G.; Oulha, A.; Bradley, K.M.; Jacoby, R.; Refsum, H. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: A randomized controlled trial. PLoS ONE 2010, 5, e12244. [Google Scholar] [CrossRef] [PubMed]
  31. De Jager, C.A.; Oulhaj, A.; Jacoby, R.; Refsum, H.; Smith, A.D. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: A randomized controlled trial. Int. J. Geriatr. Psychiatry 2012, 27, 592–600. [Google Scholar] [CrossRef] [PubMed]
  32. Douaud, G.; Refsum, H.; de Jager, C.A.; Jacoby, R.; Nichols, T.E.; Smith, S.M.; Smith, A.D. Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment. Proc. Natl. Acad. Sci. USA 2013, 110, 9523–9528. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Petersen, R.C.; Thomas, R.G.; Grundman, M.; Bennett, D.; Doody, R.; Ferris, S.; Galasko, D.; Jin, S.; Kaye, J.; Levey, A.; et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 2005, 352, 2379–2388. [Google Scholar] [CrossRef] [PubMed]
  34. Starr, J.M.; Whalley, L.J.; Deary, I.J. The effects of antihypertensive treatment on cognitive function: Results from the HOPE study. J. Am. Geriatr. Soc. 1996, 44, 411–415. [Google Scholar] [CrossRef] [PubMed]
  35. Starr, J.M.; Whalley, L.J. Differential cognitive outcomes in the Hypertensive Old People in Edinburgh study. J. Neurol. Sci. 2005, 229–230, 103–107. [Google Scholar] [CrossRef] [PubMed]
  36. Barnes, P.J. Cellular and molecular mechanisms of asthma and COPD. Clin. Sci. 2017, 131, 1541–1558. [Google Scholar] [CrossRef] [PubMed]
  37. Barnard, N.D.; Bunner, A.E.; Agarwal, U. Saturated and trans fats and dementia: A systematic review. Neurobiol. Aging 2014, 35, S65–S73. [Google Scholar] [CrossRef] [PubMed]
  38. McGeer, P.L.; Schulzer, M.; McGeer, E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: A review of 17 epidemiologic studies. Neurology 1996, 47, 425–432. [Google Scholar] [CrossRef] [PubMed]
  39. Small, G.W.; Siddarth, P.; Silverman, D.H.; Ercoli, L.M.; Miller, K.J.; Lavretsky, H.; Bookheimer, S.Y.; Huang, S.C.; Barrio, J.R.; Phelps, M.E. Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: Randomized controlled study. Am. J. Geriatr. Psychiatry 2008, 16, 999–1009. [Google Scholar] [CrossRef] [PubMed]
  40. Jack, C.R., Jr.; Petersen, R.C.; Grundman, M.; Jin, S.; Gamst, A.; Ward, C.P.; Sencakova, D.; Doody, R.S.; Thal, L.J. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol. Aging 2008, 29, 1285–1295. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  41. Hildreth, K.L.; Van Pelt, R.E.; Moreau, K.L.; Grigsby, J.; Hoth, K.F.; Pelak, V.; Anderson, C.A.; Parnes, B.; Kittelson, J.; Wolfe, P.; et al. Effects of pioglitazone or exercise in older adults with mild cognitive impairment and insulin resistance: A pilot study. Dement. Geriatr. Cogn. Dis. Extra 2015, 5, 51–63. [Google Scholar] [CrossRef] [PubMed]
  42. Luchsinger, J.A.; Perez, T.; Chang, H.; Mehta, P.; Steffener, J.; Pradabhan, G.; Ichise, M.; Manly, J.; Devanand, D.P.; Bagiella, E. Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial. J. Alzheimers Dis. 2016, 51, 501–514. [Google Scholar] [CrossRef] [PubMed]
  43. Barnes, D.E.; Yaffe, K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 2011, 10, 819–828. [Google Scholar] [CrossRef]
  44. Newhouse, P.; Kellar, K.; Aisen, P.; White, H.; Wesnes, K.; Coderre, E.; Pfaff, A.; Wilkins, H.; Howard, D.; Levin, E.D. Nicotine treatment of mild cognitive impairment: A 6-month double-blind pilot clinical trial. Neurology 2012, 78, 91–101. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Forlenza, O.V.; Diniz, B.S.; Radanovic, M.; Santos, F.S.; Talib, L.L.; Gattaz, W.F. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: Randomised controlled trial. Br. J. Psychiatry 2011, 198, 351–356. [Google Scholar] [CrossRef] [PubMed]
  46. Knopman, D.S.; Petersen, R.C. Mild cognitive impairment and mild dementia: A clinical perspective. Mayo Clin. Proc. 2014, 89, 1452–1459. [Google Scholar] [CrossRef] [PubMed]
  47. Langa, K.M.; Levine, D.A. The diagnosis and management of mild cognitive impairment: A clinical review. JAMA 2014, 312, 2551–2561. [Google Scholar] [CrossRef] [PubMed]
  48. Fink, H.A.; Jutkowitz, E.; McCarten, J.R.; Hemmy, L.S.; Butler, M.; Davila, H.; Ratner, E.; Calvert, C.; Barclay, T.R.; Brasure, M.; et al. Pharmacologic Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review. Ann. Intern. Med. 2018, 168, 39–51. [Google Scholar] [CrossRef] [PubMed]
  49. Petersen, R.C.; Lopez, O.; Armstrong, M.J.; Getchius, T.S.D.; Ganguli, M.; Gloss, D.; Gronseth, G.S.; Marson, D.; Pringsheim, T.; Day, G.S.; et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018, 90, 126–135. [Google Scholar] [CrossRef] [PubMed]
  50. Villeneuve, S.; Pepin, V.; Rahayel, S.; Bertrand, J.A.; de Lorimier, M.; Rizk, A.; Desjardins, C.; Parenteau, S.; Beaucage, F.; Joncas, S.; et al. Mild cognitive impairment in moderate to severe COPD: A preliminary study. Chest 2012, 142, 1516–1523. [Google Scholar] [CrossRef] [PubMed]
  51. Singh, B.; Parsaik, A.K.; Mielke, M.M.; Roberts, R.O.; Scanlon, P.D.; Geda, Y.E.; Pankratz, V.S.; Christianson, T.; Yawn, B.P.; Petersen, R.C. Chronic obstructive pulmonary disease and association with mild cognitive impairment: The Mayo Clinic Study of Aging. Mayo Clin. Proc. 2013, 88, 1222–1230. [Google Scholar] [CrossRef] [PubMed]
  52. Yohannes, A.M.; Chen, W.; Moga, A.M.; Leroi, I.; Connolly, M.J. Cognitive Impairment in Chronic Obstructive Pulmonary Disease and Chronic Heart Failure: A Systematic Review and Meta-analysis of Observational Studies. J. Am. Med. Dir. Assoc. 2017, 18, 451.e1–451.e11. [Google Scholar] [CrossRef] [PubMed]
  53. Ouellette, D.R.; Lavoie, K.L. Recognition, diagnosis, and treatment of cognitive and psychiatric disorders in patients with COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2017, 12, 639–650. [Google Scholar] [CrossRef] [PubMed]
  54. Li, J.; Huang, Y.; Fei, G.H. The evaluation of cognitive impairment and relevant factors in patients with chronic obstructive pulmonary disease. Respiration 2013, 85, 98–105. [Google Scholar] [CrossRef] [PubMed]
  55. Schrijvers, E.M.; Koudstaal, P.J.; Hofman, A.; Breteler, M.M. Plasma clusterin and the risk of Alzheimer disease. JAMA 2011, 305, 1322–1326. [Google Scholar] [CrossRef] [PubMed]
  56. Nuutinen, T.; Suuronen, T.; Kauppinen, A.; Salminen, A. Clusterin: A forgotten player in Alzheimer’s disease. Brain Res. Rev. 2009, 61, 89–104. [Google Scholar] [CrossRef] [PubMed]
  57. Jongbloed, W.; van Dijk, K.D.; Mulder, S.D.; van de Berg, W.D.; Blankenstein, M.A.; van der Flier, W.; Veerhuis, R. Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer’s Disease. J. Alzheimers Dis. 2015, 46, 1103–1110. [Google Scholar] [CrossRef] [PubMed]
  58. Wilson, M.R.; Zoubeidi, A. Clusterin as a therapeutic target. Expert Opin. Ther. Targets. 2017, 21, 201–213. [Google Scholar] [CrossRef] [PubMed]
  59. Carnevali, S.; Luppi, F.; D’Arca, D.; Caporali, A.; Ruggieri, M.P.; Vettori, M.V.; Caglieri, A.; Astancolle, S.; Panico, F.; Davalli, P.; et al. Clusterin decreases oxidative stress in lung fibroblasts exposed to cigarette smoke. Am. J. Respir. Crit. Care Med. 2006, 174, 393–399. [Google Scholar] [CrossRef] [PubMed]
  60. Franceschi, C.; Garagnani, P.; Morsiani, C.; Conte, M.; Santoro, A.; Grignolio, A.; Monti, D.; Capri, M.; Salvioli, S. The Continuum of Aging and Age-Related Diseases: Common Mechanisms but Different Rates. Front. Med. 2018, 5, 61. [Google Scholar] [CrossRef] [PubMed]
  61. Salimian, J.; Mirzaei, H.; Moridikia, A.; Harchegani, A.B.; Sahebkar, A.; Salehi, H. Chronic obstructive pulmonary disease: MicroRNAs and exosomes as new diagnostic and therapeutic biomarkers. J. Res. Med. Sci. 2018, 23, 27. [Google Scholar] [CrossRef] [PubMed]
  62. Zendjabil, M. Circulating microRNAs as novel biomarkers of Alzheimer’s disease. Clin. Chim. Acta 2018, 484, 99–104. [Google Scholar] [CrossRef] [PubMed]
  63. Di Domenico, F.; Barone, E.; Perluigi, M.; Butterfield, D.A. The Triangle of Death in Alzheimer’s Disease Brain: The Aberrant Cross-Talk Among Energy Metabolism, Mammalian Target of Rapamycin Signaling, and Protein Homeostasis Revealed by Redox Proteomics. Antioxid. Redox Signal. 2017, 26, 364–387. [Google Scholar] [CrossRef] [PubMed]
  64. Hashimoto, S. Autophagy in the respiratory diseases. Respir. Investig. 2016, 54, 383–384. [Google Scholar] [CrossRef] [PubMed]
  65. Fujikake, N.; Shin, M.; Shimizu, S. Association Between Autophagy and Neurodegenerative Diseases. Front. Neurosci. 2018, 12, 255. [Google Scholar] [CrossRef] [PubMed]
  66. White, J.A.; Banerjee, R.; Gunawardena, S. Axonal Transport and Neurodegeneration: How Marine Drugs Can Be Used for the Development of Therapeutics. Mar. Drugs 2016, 14, 102. [Google Scholar] [CrossRef] [PubMed]
  67. Yanagisawa, S.; Papaioannou, A.I.; Papaporfyriou, A.; Baker, J.R.; Vuppusetty, C.; Loukides, S.; Barnes, P.J.; Ito, K. Decreased Serum Sirtuin-1 in COPD. Chest 2017, 152, 343–352. [Google Scholar] [CrossRef] [PubMed]
  68. Almeida, O.P.; Morar, B.; Hankey, G.J.; Yeap, B.B.; Golledge, J.; Jablensky, A.; Flicker, L. Longevity Klotho gene polymorphism and the risk of dementia in older men. Maturitas 2017, 101, 1–5. [Google Scholar] [CrossRef] [PubMed]
  69. Suberbielle, E.; Djukic, B.; Evans, M.; Kim, D.H.; Taneja, P.; Wang, X.; Finucane, M.; Knox, J.; Ho, K.; Devidze, N.; et al. DNA repair factor BRCA1 depletion occurs in Alzheimer brains and impairs cognitive function in mice. Nat. Commun. 2015, 6, 8897. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  70. Milic, M.; Frustaci, A.; Del Bufalo, A.; Sánchez-Alarcón, J.; Valencia-Quintana, R.; Russo, P.; Bonassi, S. DNA damage in non-communicable diseases: A clinical and epidemiological perspective. Mutat. Res. 2015, 776, 118–127. [Google Scholar] [CrossRef] [PubMed]
  71. Sethi, G.S.; Dharwal, V.; Naura, A.S. Poly(ADP-Ribose)Polymerase-1 in Lung Inflammatory Disorders: A Review. Front. Immunol. 2017, 8, 1172. [Google Scholar] [CrossRef] [PubMed]
  72. Jang, J.H.; Chand, H.S.; Bruse, S.; Doyle-Eisele, M.; Royer, C.; McDonald, J.; Qualls, C.; Klingelhutz, A.J.; Lin, Y.; Mallampalli, R.; et al. Connective Tissue Growth Factor Promotes Pulmonary Epithelial Cell Senescence and Is Associated with COPD Severity. COPD 2017, 14, 228–237. [Google Scholar] [CrossRef] [PubMed]
  73. Tsuji, T.; Aoshiba, K.; Nagai, A. Alveolar cell senescence in patients with pulmonary emphysema. Am. J. Respir. Crit. Care Med. 2006, 174, 886–893. [Google Scholar] [CrossRef] [PubMed]
  74. Nativio, R.; Donahue, G.; Berson, A.; Lan, Y.; Amlie-Wolf, A.; Tuzer, F.; Toledo, J.B.; Gosai, S.J.; Gregory, B.D.; Torres, C.; et al. Dysregulation of the epigenetic landscape of normal aging in Alzheimer’s disease. Nat. Neurosci. 2018, 21, 497–505. [Google Scholar] [CrossRef] [PubMed]
  75. Larbi, A.; Pawelec, G.; Witkowski, J.M.; Schipper, H.M.; Derhovanessian, E.; Goldeck, D.; Fulop, T. Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer’s disease. J. Alzheimers Dis. 2009, 17, 91–103. [Google Scholar] [CrossRef] [PubMed]
  76. Cheng, Y.; Bai, F. The Association of Tau With Mitochondrial Dysfunction in Alzheimer’s Disease. Front. Neurosci. 2018, 12, 163. [Google Scholar] [CrossRef] [PubMed]
  77. Ghosh, M.; Miller, Y.E.; Nakachi, I.; Kwon, J.B.; Barón, A.E.; Brantley, A.E.; Merrick, D.T.; Franklin, W.A.; Keith, R.L.; Vandivier, R.W. Exhaustion of Airway Basal Progenitor Cells in Early and Established Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit Care Med. 2018, 197, 885–896. [Google Scholar] [CrossRef] [PubMed]
  78. Scarabino, D.; Broggio, E.; Gambina, G.; Corbo, R.M. Leukocyte telomere length in mild cognitive impairment and Alzheimer’s disease patients. Exp. Gerontol. 2017, 98, 143–147. [Google Scholar] [CrossRef] [PubMed]
  79. Lamonaca, P.; Prinzi, G.; Kisialiou, A.; Cardaci, V.; Fini, M.; Russo, P. Metabolic Disorder in Chronic Obstructive Pulmonary Disease (COPD) Patients: Towards a Personalized Approach Using Marine Drug Derivatives. Mar. Drugs 2017, 15, 81. [Google Scholar] [CrossRef] [PubMed]
  80. Jia, W.; Gao, W.Y.; Yan, Y.Q.; Wang, J.; Xu, Z.H.; Zheng, W.J.; Xiao, P.G. The rediscovery of ancient Chinese herbal formulas. Phytother. Res. 2004, 18, 681–686. [Google Scholar] [CrossRef] [PubMed]
  81. Nastrucci, C.; Cesario, A.; Russo, P. Anticancer drug discovery from the marine environment. Recent Pat. Anticancer Drug Discov. 2012, 7, 218–232. [Google Scholar] [CrossRef] [PubMed]
  82. Russo, P.; Cesario, A. New anticancer drugs from marine cyanobacteria. Curr. Drug Targets 2012, 13, 1048–1053. [Google Scholar] [CrossRef] [PubMed]
  83. Russo, P.; Del Bufalo, A.; Fini, M. Deep sea as a source of novel-anticancer drugs: Update on discovery and preclinical/clinical evaluation in a systems medicine perspective. EXCLI J. 2015, 14, 228–236. [Google Scholar] [PubMed]
  84. Russo, P.; Kisialiou, A.; Lamonaca, P.; Moroni, R.; Prinzi, G.; Fini, M. New Drugs from Marine Organisms in Alzheimer’s Disease. Mar. Drugs 2016, 14, 5. [Google Scholar] [CrossRef] [PubMed]
  85. Ma, S.Y.; Park, W.S.; Lee, D.S.; Choi, G.; Yim, M.J.; Lee, J.M.; Jung, W.K.; Park, S.G.; Seo, S.K.; Park, S.J.; et al. Fucoxanthin inhibits profibrotic protein expression in vitro and attenuates bleomycin-induced lung fibrosis in vivo. Eur. J. Pharmacol. 2017, 811, 199–207. [Google Scholar] [CrossRef] [PubMed]
  86. Ning, C.; Wang, H.D.; Gao, R.; Chang, Y.C.; Hu, F.; Meng, X.; Huang, S.Y. Marine-derived protein kinase inhibitors for neuroinflammatory diseases. Biomed. Eng. Online 2018, 17, 46. [Google Scholar] [CrossRef] [PubMed]
  87. Kao, C.J.; Chen, W.F.; Guo, B.L.; Feng, C.W.; Hung, H.C.; Yang, W.Y.; Sung, C.S.; Tsui, K.H.; Chu, H.; Chen, N.F.; et al. The 1-Tosylpentan-3-one Protects against 6-Hydroxydopamine-Induced Neurotoxicity. Int. J. Mol. Sci. 2017, 18, 1096. [Google Scholar] [CrossRef] [PubMed]
  88. Kim, D.C.; Cho, K.H.; Ko, W.; Yoon, C.S.; Sohn, J.H.; Yim, J.H.; Kim, Y.C.; Oh, H. Anti-Inflammatory and Cytoprotective Effects of TMC-256C1 from Marine-Derived Fungus Aspergillus sp. SF-6354 via up-Regulation of Heme Oxygenase-1 in Murine Hippocampal and Microglial Cell Lines. Int. J. Mol. Sci. 2016, 17, 529. [Google Scholar] [CrossRef] [PubMed]
  89. Yang, W.; Luo, Y.; Tang, R.; Zhang, H.; Ye, Y.; Xiang, L.; Qi, J. Neuritogenic monoglyceride derived from the constituent of a marine fish for activating the PI3K/ERK/CREB signalling pathways in PC12 cells. Int. J. Mol. Sci. 2013, 14, 24200–24210. [Google Scholar] [CrossRef] [PubMed]
  90. Tsang, C.K.; Kamei, Y. Sargaquinoic acid supports the survival of neuronal PC12D cells in a nerve growth factor-independent manner. Eur. J. Pharmacol. 2004, 488, 11–18. [Google Scholar] [CrossRef] [PubMed]
  91. Jang, J.H.; Lee, J.H.; Chand, H.S.; Lee, J.S.; Lin, Y.; Weathington, N.; Mallampalli, R.; Jeon, Y.J.; Nyunoya, T. APO-9′-Fucoxanthinone Extracted from Undariopsis peteseniana Protects Oxidative Stress-Mediated Apoptosis in Cigarette Smoke-Exposed Human Airway Epithelial Cells. Mar. Drugs 2016, 14, 144. [Google Scholar] [CrossRef] [PubMed]
  92. Li, Q.; Wu, F.; Wen, M.; Yanagita, T.; Xue, C.; Zhang, T.; Wang, Y. The Protective Effect of Antarctic Krill Oil on Cognitive Function by Inhibiting Oxidative Stress in the Brain of Senescence-Accelerated Prone Mouse Strain 8 (SAMP8) Mice. J. Food Sci. 2018, 83, 543–551. [Google Scholar] [CrossRef] [PubMed]
  93. Hsu, W.H.; Lin, Y.C.; Chen, B.R.; Wu, S.C.; Lee, B.H. The neuronal protection of a zinc-binding protein isolated from oyster. Food Chem. Toxicol. 2018, 114, 61–68. [Google Scholar] [CrossRef] [PubMed]
  94. Leirós, M.; Alonso, E.; Rateb, M.E.; Houssen, W.E.; Ebel, R.; Jaspars, M.; Alfonso, A.; Botana, L.M. Gracilins: Spongionella-derived promising compounds for Alzheimer disease. Neuropharmacology 2015, 93, 285–293. [Google Scholar] [CrossRef] [PubMed]
  95. Leirós, M.; Sánchez, J.A.; Alonso, E.; Rateb, M.E.; Houssen, W.E.; Ebel, R.; Jaspars, M.; Alfonso, A.; Botana, L.M. Spongionella secondary metabolites protect mitochondrial function in cortical neurons against oxidative stress. Mar. Drugs 2014, 12, 700–718. [Google Scholar] [CrossRef] [PubMed]
  96. Mokdad, A.H.; Ballestros, K.; Echko, M.; Glenn, S.; Olsen, H.E.; Mullany, E.; Lee, A.; Khan, A.R.; Ahmadi, A.; Ferrari, A.J.; et al. The State of US Health, 1990–2016: Burden of Diseases, Injuries, and Risk Factors Among US States. JAMA 2018, 319, 1444–1472. [Google Scholar] [PubMed]
  97. Annuario Statistico Italiano 2017; Istat: Roma, Italy, 2017.
  98. Calverley, P.M.; Anderson, J.A.; Celli, B.; Ferguson, G.T.; Jenkins, C.; Jones, P.W.; Yates, J.C.; Vestbo, J.; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007, 356, 775–789. [Google Scholar] [PubMed]
  99. Germini, F.; Veronese, G.; Marcucci, M.; Coen, D.; Ardemagni, D.; Montano, N.; Fabbri, A.; SIMEU Study Group. COPD exacerbations in the emergency department: Epidemiology and related costs. A retrospective cohort multicentre study from the Italian Society of Emergency Medicine (SIMEU). Eur. J. Intern. Med. 2018, 51, 74–79. [Google Scholar] [CrossRef] [PubMed]
  100. Grant, I.; Heaton, R.K.; McSweeny, A.J.; Adams, K.M.; Timms, R.M. Neuropsychologic findings in hypoxemic chronic obstructive pulmonary disease. Arch. Intern. Med. 1982, 142, 1470–1476. [Google Scholar] [CrossRef] [PubMed]
  101. Chang, S.S.; Chen, S.; McAvay, G.J.; Tinetti, M.E. Effect of coexisting chronic obstructive pulmonary disease and cognitive impairment on health outcomes in older adults. J. Am. Geriatr. Soc. 2012, 60, 1839–1846. [Google Scholar] [CrossRef] [PubMed]
  102. Dodd, J.W.; Charlton, R.A.; van den Broek, M.D.; Jones, P.W. Cognitive dysfunction in patients hospitalized with acute exacerbation of COPD. Chest 2013, 144, 119–127. [Google Scholar] [CrossRef] [PubMed]
  103. Baird, C.; Lovell, J.; Johnson, M.; Shiell, K.; Ibrahim, J.E. The impact of cognitive impairment on self-management in chronic obstructive pulmonary disease: A systematic review. Respir. Med. 2017, 129, 130–139. [Google Scholar] [CrossRef] [PubMed]
  104. Allen, S.C.; Baxter, M. A comparison of four tests of cognition as predictors of inability to perform spirometry in old age. Age Ageing 2009, 38, 537–541. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  105. Turkeshi, E.; Zelenukha, D.; Vaes, B.; Andreeva, E.; Frolova, E.; Degryse, J.M. Predictors of poor-quality spirometry in two cohorts of older adults in Russia and Belgium: A cross-sectional study. NPJ Prim. Care Respir. Med. 2015, 25, 15048. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  106. Knorr-Held, L.; Best, N.G. A shared component model for detecting joint and selective clustering of two diseases. J. Royal Statist. Soc. 2001, 164, 73–85. [Google Scholar] [CrossRef] [Green Version]
  107. Loscalzo, J.; Kohane, I.; Barabasi, A.L. Human disease classification in the postgenomic era: A complex systems approach to human pathobiology. Mol. Syst. Biol. 2007, 3, 124. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  108. Lococo, F.; Cesario, A.; Del Bufalo, A.; Ciarrocchi, A.; Prinzi, G.; Mina, M.; Bonassi, S.; Russo, P. Novel therapeutic strategy in the management of COPD: A systems medicine approach. Curr. Med. Chem. 2015, 22, 3655–3675. [Google Scholar] [CrossRef] [PubMed]
  109. Iyengar, R.; Zhao, S.; Chung, S.W.; Mager, D.E.; Gallo, J.M. Merging systems biology with pharmacodynamics. Sci. Transl. Med. 2012, 4, 126ps7. [Google Scholar] [CrossRef] [PubMed]
  110. Harrold, J.M.; Ramanathan, M.; Mager, D.E. Network-based approaches in drug discovery and early development. Clin. Pharmacol. Ther. 2013, 94, 651–658. [Google Scholar] [CrossRef] [PubMed]
  111. Lin, J.; Huang, L.; Yu, J.; Xiang, S.; Wang, J.; Zhang, J.; Yan, X.; Cui, W.; He, S.; Wang, Q. Fucoxanthin, a Marine Carotenoid, Reverses Scopolamine-Induced Cognitive Impairments in Mice and Inhibits Acetylcholinesterase in Vitro. Mar. Drugs 2016, 14, 77. [Google Scholar] [CrossRef] [PubMed]
  112. Kumar, M.S.; Adki, K.M. Marine natural products for multi-targeted cancer treatment: A future insight. Biomed. Pharmacother. 2018, 105, 233–245. [Google Scholar] [CrossRef] [PubMed]
Marinedrugs 16 00313 g001 550
Figure 1. Fucoxanthin.
Figure 1. Fucoxanthin.
Marinedrugs 16 00313 g001
Marinedrugs 16 00313 g002 550
Figure 2. Austrasulfone.
Figure 2. Austrasulfone.
Marinedrugs 16 00313 g002
Marinedrugs 16 00313 g003 550
Figure 3. TMC-256C1.
Figure 3. TMC-256C1.
Marinedrugs 16 00313 g003
Marinedrugs 16 00313 g004 550
Figure 4. 1-O-(Myristoyl) glycerol.
Figure 4. 1-O-(Myristoyl) glycerol.
Marinedrugs 16 00313 g004
Marinedrugs 16 00313 g005 550
Figure 5. Sargaquinoic acid.
Figure 5. Sargaquinoic acid.
Marinedrugs 16 00313 g005
Marinedrugs 16 00313 g006 550
Figure 6. Bafilomycin.
Figure 6. Bafilomycin.
Marinedrugs 16 00313 g006
Marinedrugs 16 00313 g007 550
Figure 7. Coibamide A.
Figure 7. Coibamide A.
Marinedrugs 16 00313 g007
Marinedrugs 16 00313 g008 550
Figure 8. Manzamine A.
Figure 8. Manzamine A.
Marinedrugs 16 00313 g008
Marinedrugs 16 00313 g009 550
Figure 9. Papuamine.
Figure 9. Papuamine.
Marinedrugs 16 00313 g009
Marinedrugs 16 00313 g010 550
Figure 10. Apo-9′-fucoxanthinone.
Figure 10. Apo-9′-fucoxanthinone.
Marinedrugs 16 00313 g010
Marinedrugs 16 00313 g011 550
Figure 11. Omega-3 fatty acids. (a) Alpha-linolenic acid. (b) Docosahexaenoic acid. (c) Eicosapentaenoic acid.
Figure 11. Omega-3 fatty acids. (a) Alpha-linolenic acid. (b) Docosahexaenoic acid. (c) Eicosapentaenoic acid.
Marinedrugs 16 00313 g011
Marinedrugs 16 00313 g012 550
Figure 12. Phosphatidylcholine (a) and gracilin (b).
Figure 12. Phosphatidylcholine (a) and gracilin (b).
Marinedrugs 16 00313 g012
Table
Table 1. Biomarkers to assess mild cognitive impairement (MCI) according to National Institute on Aging-Alzheimer’s Association (NIA-AA) [14].
Table 1. Biomarkers to assess mild cognitive impairement (MCI) according to National Institute on Aging-Alzheimer’s Association (NIA-AA) [14].
MarkersMethodologyReferences
AD PATHOLOGY
Biomarkers of amyloid
(Aβ) deposition		-Cerebrospinal fluid (CSF) concentrations of Aβ42 (decreased CSF Aβ42 levels)
-Positron emission tomography (PET) amyloid imaging		[14,15]
Biomarkers of neuronal injury-CSF concentrations of /phosphorylated(increased CSF/p levels)
-Hippocampal volume or medial temporal atrophy or rate of brain atrophy measured by structural MRI
-Decreased glucose metabolism in temporoparietal regions on fluorodeoxyglucose PET imaging		[15,16,17]
Presence of AD genetic risk factorsVariation in apolipoprotein E
gene located on chromosome 19		[18,19]
LEWY BODY PATHOLOGY
-Visual hallucinations
-Parkinsonism
-Motor features (bradykinesia, rigidity)
-Rapid eye movement during sleep
-Abnormalities suggesting pathological processes associated with dementia and with Lewy bodies (DLB)		 [20]
VASCULAR DISEASE
Multiple vascular risk factors suggesting pathological processes associated with vascular dementia-Presence of extensive
cerebrovascular disease evident by structural MRI
-“Step-wise” decline		[21]
FRONTOTEMPORAL DEGENERATION
-Frontal lobe atrophy evident by structural MRI
-Decreased glucose metabolism in the frontal and temporal lobes evident by PET
-Mutations in the microtubule-associatedprotein gene on chromosome 17		[22]
Table
Table 2. Overview of different interventions in adults with MCI.
Table 2. Overview of different interventions in adults with MCI.
InterventionRationaleKey MessageReferences
NutraceuticalsTargeted pathways include:
-reducing oxidative stress and chronic inflammation
-improving vascular function
-supplementing macronutrients found in brain tissue and used in brain function		Few studies examined the effects of nutraceuticals on adults with MCI (i.e., omega-3, fatty acids, ginkgo biloba)[24,25,26]
Hormone therapySpeculation of the relationship between the pituitary endocrine axis and aging-Low-strength evidence suggests that estrogen therapy may slightly increase the risk of probable MCI
-Low-strength evidence suggests that faloxifene may decrease the risk of MCI compared to placebo
-No effect of soybean-derived phosphatidylserine
-Hormone therapy has been associated with serious adverse events, including increased risk of certain cancers and cardiovascular disease		[27,28]
Vitamin(s)In the case of B vitamins the targeted pathway may involve lowering of homocysteine levels-Moderate-strength evidence shows no benefit in cognitive performance for vitamin E in women
-B vitamins show mixed findings
-Low-strength evidence shows no benefit in cognitive performance for multivitamins, vitamin C (in women), vitamin D with calcium (in women), or
-carotene (in women)
-Low-strength evidence shows no benefit in incident MCI for multivitamins or vitamin D with calcium
-In adults with MCI, low-strength evidence shows no benefit for vitamin E		[29,30,31,32,33]
AntihypertensiveHypertension is thought to contribute to risk of both vascular and AD dementia through unclear vascular mechanisms.
Presumably hypertension is the cause or result of vascular changes in the blood supply to the brain that can adversely affect its function.
It remains unclear whether this is a direct effect or the result of other factors that affect both the vasculature and the brain.		Generally, low-strength evidence shows that 3 to 4.7 years of antihypertensive treatment regimens versus placebo appears to have no benefit on cognitive test performance in adults MCI[34,35,36]
Lipid lowering treatmentSaturated fat intake is positively associated with MCI, or cognitive decline.Evidence was insufficient to assess the effect of 5 years statin treatment on preventing MCI[37]
Non-steroidal antiinflammatory drugs (NSAIDs)Numerous epidemiological studies have shown an association between NSAID use and a reduced prevalence of dementia, specifically AD.
In vitro and animal models of AD pathology show that NSAIDs reduce plaque-related inflammation and improve function, both at a cellular and behavioral level		No evidence is available for the effect of low-dose aspirin on MCI[38,39]
Anti-dementiaThe acetylcholinesterase inhibitors (AChEIs) have consistently demonstrated a modest but positive benefit to cognition in persons with mild through severe stages. They may likewise provide benefit to persons with age-related cognitive decline or MCI through the same mechanisms of action by increasing the duration of action of acetylcholine in the synapse through inhibition of its breakdown by AChE. The drugs have been approved by the FDA/EMA for people with mild to moderate AD but not for people with age-related cognitive decline or MCI.-Low-strength evidence shows AChEIs do not reduce the incidence of AD in persons with MCI for over 3 years
-Low-strength evidence shows AChEIs for 3 years have no significant effect on cognitive performance in adults with MCI		[33,40]
Diabetes medicationDiabetes may increase risk of AD through:
-vascular mechanisms
-direct effects of elevated blood glucose
-insulin-resistance associated inflammation, and/or a pathway in which peripheral hyperinsulinemia inhibits brain insulin production, which then results in impaired brain Aclearance		No studies report on the effect of diabetes treatment on the risk of incident clinical diagnoses of MCI.[41,42,43]
Other drugs Evidence was insufficient for lithium, or for nicotine patch[44,45]
Adapted from reference 23.
Table
Table 3. Marine bioactive compounds acting on different targets shared by COPD and MCI/AD.
Table 3. Marine bioactive compounds acting on different targets shared by COPD and MCI/AD.
DrugMechanismReferences
COPDMCI/AD
Activation PI3K-mTOR
FucoxanthinInhibition of mice bleomicyn-induced lung fibrosisNeuroprotective[85,86]
AustrasulfoneNAAnti-apoptotic[87]
TMC-256C1NAActivation of kinases[88]
1-O-(Myristoyl) glycerol (MG)NANeurite outgrowth[89]
Sargaquinoic acidNAEnhancement of neuriteregeneration[90]
Altered autophagy
Bafilomycins,
coibamide A,
manzamine A and
papuamine		NAInhibits autophagy
Induces autophagy
Induces autophagy		[66]
Defective DNA damage repair
Apo-9′-fucoxanthinoneDecreases cigarette smoke extract-induced
DNA damage		 [91]
Cellular senescence
Antarctic krill oil (AKO)NA-Protective effect against AD senescence
-Ameliorates learning and memory deficits and eases the anxiety
-Reduces Aβ accumulation		[92]
Mitochondrial dysfunction
43 kD proteinNA-Attenuates neuronal cell death.
-Alleviates mitochondrial inactivation
-Recovers metallathionein-3 (MT-3)
-Decreases and inhibits β- and γ-secretase, as well as Aβ accumulation		[93]
GracilinsNA-Positive trend on learning and spatial memory of treated mice. --Decreases Aβ42 and hyperphosphorylated levels
-Preserves neurons against oxidative damage		[94,95]

Share and Cite

MDPI and ACS Style

Prinzi, G.; Santoro, A.; Lamonaca, P.; Cardaci, V.; Fini, M.; Russo, P. Cognitive Impairment in Chronic Obstructive Pulmonary Disease (COPD): Possible Utility of Marine Bioactive Compounds. Mar. Drugs 2018, 16, 313. https://doi.org/10.3390/md16090313

AMA Style

Prinzi G, Santoro A, Lamonaca P, Cardaci V, Fini M, Russo P. Cognitive Impairment in Chronic Obstructive Pulmonary Disease (COPD): Possible Utility of Marine Bioactive Compounds. Marine Drugs. 2018; 16(9):313. https://doi.org/10.3390/md16090313

Chicago/Turabian Style

Prinzi, Giulia, Alessia Santoro, Palma Lamonaca, Vittorio Cardaci, Massimo Fini, and Patrizia Russo. 2018. "Cognitive Impairment in Chronic Obstructive Pulmonary Disease (COPD): Possible Utility of Marine Bioactive Compounds" Marine Drugs 16, no. 9: 313. https://doi.org/10.3390/md16090313

APA Style

Prinzi, G., Santoro, A., Lamonaca, P., Cardaci, V., Fini, M., & Russo, P. (2018). Cognitive Impairment in Chronic Obstructive Pulmonary Disease (COPD): Possible Utility of Marine Bioactive Compounds. Marine Drugs, 16(9), 313. https://doi.org/10.3390/md16090313

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop